OPT - Opthea surges 41% as potential beneficiary of Clearside wet AMD data

Shares of Opthea (OPT) are up 41% in afternoon trading, possibly due to a data release yesterday from Clearside Biomedical (CLSD) on its wet age-related macular degeneration ("AMD") candidate.Earlier in the day, Opthea reached a 52-week high of $16.23.In a phase 2b trial, Opthea's lead candidate, OPT-302, when giving together with Roche's Lucentis (ranibizumab), was superior to Lucentis alone in untreated wet AMD patients.Opthea started treatment in the first patient in its phase 3 trial for OPT-302 in March.

For further details see:

Opthea surges 41% as potential beneficiary of Clearside wet AMD data